Welcome to our dedicated page for Radius Recycling news (Ticker: RDUS), a resource for investors and traders seeking the latest updates and insights on Radius Recycling stock.
Radius Recycling Inc (RDUS) operates North America's premier vertically integrated metals platform, combining recycling operations with auto parts retail and steel production. This page serves as the definitive source for corporate announcements, financial results, and operational developments across all business segments.
Investors and industry professionals will find curated press releases covering quarterly earnings, sustainability initiatives, facility expansions, and strategic partnerships. Our news collection prioritizes official statements about metal recovery innovations, retail network growth, and manufacturing process enhancements.
Key content categories include updates on ferrous/nonferrous market positioning, automotive parts distribution milestones, and steel product innovations. All materials are organized chronologically to help track the company's progress in optimizing its integrated value chain.
Bookmark this page for direct access to primary source materials about RDUS's operational strategies. Check back for real-time updates on how the company maintains leadership through technological investments and supply chain management in the recycling sector.
Gurnet Point Capital and Patient Square Capital have successfully completed their acquisition of Radius Health (Nasdaq: RDUS) for $10.00 per share in cash, plus a contingent value right to receive an additional $1.00 if TYMLOS sales exceed $300 million by 2025. Radius, known for its lead product TYMLOS, which treats osteoporosis in postmenopausal women, will be delisted from NASDAQ following the merger. The acquisition aligns with the investors’ strategy to enhance operational efficiencies in healthcare.
The Menarini Group and Stemline Therapeutics announced that the FDA has accepted the New Drug Application (NDA) for elacestrant, an investigational selective estrogen receptor degrader (SERD) for patients with ER+/HER2- advanced or metastatic breast cancer. The NDA, supported by the positive results of the Phase 3 EMERALD study, demonstrates elacestrant's significant efficacy over standard-of-care treatments. The FDA has assigned a PDUFA date of February 17, 2023, and granted Priority Review designation, indicating its potential to improve treatment options significantly.
The Menarini Group and Stemline Therapeutics announced the FDA's acceptance of the New Drug Application (NDA) for elacestrant, a potential treatment for ER+/HER2- advanced or metastatic breast cancer. The FDA has granted Priority Review with a PDUFA date of February 17, 2023. The NDA is supported by Phase 3 EMERALD study results, showing elacestrant's statistically significant efficacy over standard treatment, with a 30% reduced risk of progression in all patients and a 45% reduction in patients with ESR1 mutations. Elacestrant remains investigational and not yet FDA-approved.
Velan Capital Investment Management and Repertoire Partners, holding approximately 7.7% of Radius Health's outstanding shares, announced their withdrawal of director nominations following a proposed sale to Gurnet Point Capital and Patient Square Capital. They believe the sale price does not fully reflect the value of the company and its assets, but express satisfaction that their involvement may help stockholders recover some lost value under the current Board of Directors. They also thanked their qualified director candidates and supporters.
Radius Health, Inc. (Nasdaq: RDUS) encourages stockholders to vote 'FOR' their independent director nominees – Catherine J. Friedman, Jean-Pierre Garnier, Ph.D., and Andrew C. von Eschenbach, M.D. – using the BLUE proxy card ahead of their Annual Meeting on July 26, 2022. The company also shared an investor presentation detailing its progress since 2020 and the board's unanimous approval of a significant acquisition by Gurnet Point Capital and Patient Square Capital, offering stockholders a premium on their shares.
Radius Health announced the initiation of the SCOUT-015 pivotal study for RAD011, a synthetic cannabidiol solution targeting hyperphagia in Prader-Willi Syndrome (PWS), affecting 20,000-30,000 patients in the US. The trial, currently featuring 9 active US sites, aims for over 30 global locations and includes multiple dose assessments. RAD011 has received Orphan Drug Designation and Fast Track status from the FDA. Presentations about SCOUT-015 are planned at upcoming conferences. Radius continues to seek patient recruitment to advance this critical clinical trial.
